Bosh sahifaSOBI ā¢ STO
add
Swedish Orphan Biovitrum AB (publ)
Yopilish kursi
285,20Ā kr
Kunlik diapazon
280,20Ā kr - 286,40Ā kr
Yillik diapazon
241,80Ā kr - 354,40Ā kr
Bozor kapitalizatsiyasi
101,60Ā mlrd SEK
OŹ»rtacha hajm
328,85Ā ming
Narx/foyda
25,00
Dividend daromadliligi
-
Asosiy maydon
STO
Yangiliklarda
Moliyaviy axborot
Moliyaviy hisobot
Daromad
Sof foyda
| (SEK) | mar, 2025info | Y/Y qiyosi |
|---|---|---|
Daromad | 6,46Ā mlrd | 3,34% |
Joriy xarajat | 3,52Ā mlrd | 7,71% |
Sof foyda | 875,00Ā mln | 9,38% |
Sof foyda marjasi | 13,53 | 5,79% |
Har bir ulushga tushum | 2,72 | 1,87% |
EBITDA | 2,39Ā mlrd | 0,42% |
Amaldagi soliq stavkasi | 20,16% | ā |
Balans
Jami aktivlari
Jami passivlari
| (SEK) | mar, 2025info | Y/Y qiyosi |
|---|---|---|
Naqd pul va qisqa investitsiyalar | 997,00Ā mln | 89,18% |
Jami aktivlari | 70,12Ā mlrd | -5,90% |
Jami passivlari | 31,08Ā mlrd | -19,51% |
Umumiy kapital | 39,04Ā mlrd | ā |
Tarqatilgan aksiyalar | 343,46Ā mln | ā |
Narxi/balansdagi bahosi | 2,51 | ā |
Aktivlardan daromad | 4,98% | ā |
Kapitaldan daromad | 6,58% | ā |
Pul aylanmasi
Naqd pulning sof oŹ»zgarishi
| (SEK) | mar, 2025info | Y/Y qiyosi |
|---|---|---|
Sof foyda | 875,00Ā mln | 9,38% |
Operatsiyalardan naqd pul | 2,30Ā mlrd | 1,73% |
Sarmoyadan naqd pul | -94,00Ā mln | 87,38% |
Moliyadan naqd pul | -2,29Ā mlrd | -22,95% |
Naqd pulning sof oŹ»zgarishi | -143,00Ā mln | 62,07% |
BoŹ»sh pul | 2,38Ā mlrd | 2Ā 297,81% |
Haqida
Swedish Orphan Biovitrum AB is an international biopharmaceutical company dedicated to treatments in the areas of haematology, immunology and specialty care, based in Stockholm, Sweden.
In 2020 it had a revenue of SEK 15.261 billion and 1,509 employees. Wikipedia
Tashkil etilgan
1939
Sayt
Xodimlar soni
1Ā 895
